T TRAVERE THERAPEUTICS INC
$28.60
| Market Cap | $2.64B |
| P/E Ratio | — |
| Forward P/E | 6.71 |
| Dividend Yield | — |
| Beta | 0.88 |
| 52W Range | $12.91 - $42.13 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 65 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 25,098 | $31.46 | $789.58K | 01 Apr 2026 | 01 Apr 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 34,902 | $30.55 | $1.07M | 01 Apr 2026 | 01 Apr 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 10,000 | $30.00 | $300.00K | 01 Apr 2026 | 01 Apr 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 10,000 | $28.09 | $280.86K | 16 Mar 2026 | 16 Mar 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 60,000 | $30.10 | $1.81M | 20 Feb 2026 | 24 Feb 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 5,679 | $27.50 | $156.20K | 17 Feb 2026 | 19 Feb 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 4,321 | $28.26 | $122.12K | 17 Feb 2026 | 19 Feb 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 110 | $32.90 | $3.62K | 04 Feb 2026 | 05 Feb 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 1,635 | $32.14 | $52.55K | 04 Feb 2026 | 05 Feb 2026 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 232 | $32.85 | $7.62K | 04 Feb 2026 | 05 Feb 2026 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 1,547 | $32.11 | $49.67K | 04 Feb 2026 | 05 Feb 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 509 | $32.74 | $16.66K | 04 Feb 2026 | 05 Feb 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 2,485 | $32.07 | $79.69K | 04 Feb 2026 | 05 Feb 2026 |
| Christopher R. ClineCHIEF FINANCIAL OFFICER | Sale | 1,635 | $32.14 | $52.55K | 04 Feb 2026 | 05 Feb 2026 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 232 | $32.85 | $7.62K | 04 Feb 2026 | 05 Feb 2026 |
| Elizabeth E ReedChief Legal Officer and GC | Sale | 2,485 | $32.07 | $79.69K | 04 Feb 2026 | 05 Feb 2026 |
| Elizabeth E ReedChief Legal Officer and GC | Sale | 509 | $32.74 | $16.66K | 04 Feb 2026 | 05 Feb 2026 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 1,547 | $32.11 | $49.67K | 04 Feb 2026 | 05 Feb 2026 |
| Christopher R. ClineCHIEF FINANCIAL OFFICER | Sale | 110 | $32.90 | $3.62K | 04 Feb 2026 | 05 Feb 2026 |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 4,333 | $32.12 | $139.18K | 03 Feb 2026 | 03 Feb 2026 |
| Heerma PeterCHIEF COMMERCIAL OFFICER | Sale | 7,310 | $32.12 | $234.80K | 03 Feb 2026 | 03 Feb 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 7,175 | $32.12 | $230.46K | 03 Feb 2026 | 03 Feb 2026 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 6,956 | $32.12 | $223.43K | 03 Feb 2026 | 03 Feb 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sale | 12,446 | $32.87 | $409.10K | 03 Feb 2026 | 03 Feb 2026 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 7,242 | $32.12 | $232.61K | 03 Feb 2026 | 03 Feb 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 33,635 | $32.70 | $1.10M | 03 Feb 2026 | 03 Feb 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 66,452 | $32.06 | $2.13M | 03 Feb 2026 | 03 Feb 2026 |
| Christopher R. ClineCHIEF FINANCIAL OFFICER | Sale | 7,242 | $32.12 | $232.61K | 03 Feb 2026 | 03 Feb 2026 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 6,956 | $32.12 | $223.43K | 03 Feb 2026 | 03 Feb 2026 |
| Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | Sale | 4,333 | $32.12 | $139.18K | 03 Feb 2026 | 03 Feb 2026 |
| Eric M DubeCHIEF EXECUTIVE OFFICER | Sale | 66,452 | $32.06 | $2.13M | 03 Feb 2026 | 03 Feb 2026 |
| William E. RoteChief Research Officer | Sale | 12,446 | $32.87 | $409.10K | 03 Feb 2026 | 03 Feb 2026 |
| Elizabeth E ReedChief Legal Officer and GC | Sale | 7,175 | $32.12 | $230.46K | 03 Feb 2026 | 03 Feb 2026 |
| Peter HeermaCHIEF COMMERCIAL OFFICER | Sale | 7,310 | $32.12 | $234.80K | 03 Feb 2026 | 03 Feb 2026 |
| Eric M DubeCHIEF EXECUTIVE OFFICER | Sale | 33,635 | $32.70 | $1.10M | 03 Feb 2026 | 03 Feb 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 51,865 | $30.10 | $1.56M | 27 Jan 2026 | 27 Jan 2026 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 8,135 | $30.01 | $244.15K | 23 Jan 2026 | 27 Jan 2026 |
| REED ELIZABETH EChief Legal Officer and GC | Sale | 10,000 | $27.34 | $273.42K | 20 Jan 2026 | 21 Jan 2026 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 445 | $37.75 | $16.80K | 06 Jan 2026 | 07 Jan 2026 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 445 | $37.75 | $16.80K | 06 Jan 2026 | 07 Jan 2026 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 2,031 | $40.18 | $81.61K | 05 Jan 2026 | 07 Jan 2026 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 2,031 | $40.18 | $81.61K | 05 Jan 2026 | 07 Jan 2026 |
| ROTE WILLIAM E.Chief Research Officer | Sale | 60,000 | $40.10 | $2.41M | 24 Dec 2025 | 29 Dec 2025 |
| Inrig JulaCHIEF MEDICAL OFFICER | Sale | 15,000 | $42.00 | $630.00K | 24 Dec 2025 | 29 Dec 2025 |
| Heerma PeterCHIEF COMMERCIAL OFFICER | Sale | 4,980 | $40.00 | $199.20K | 24 Dec 2025 | 29 Dec 2025 |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 7,402 | $40.00 | $296.08K | 24 Dec 2025 | 29 Dec 2025 |
| Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | Sale | 7,402 | $40.00 | $296.08K | 24 Dec 2025 | 29 Dec 2025 |
| Peter HeermaCHIEF COMMERCIAL OFFICER | Sale | 4,980 | $40.00 | $199.20K | 24 Dec 2025 | 29 Dec 2025 |
| William E. RoteChief Research Officer | Sale | 60,000 | $40.10 | $2.41M | 24 Dec 2025 | 29 Dec 2025 |
| Jula InrigCHIEF MEDICAL OFFICER | Sale | 15,000 | $42.00 | $630.00K | 24 Dec 2025 | 29 Dec 2025 |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 2,910 | $36.00 | $104.76K | 15 Dec 2025 | 16 Dec 2025 |
| Cline Christopher R.CHIEF FINANCIAL OFFICER | Sale | 20,000 | $35.01 | $700.20K | 01 Dec 2025 | 03 Dec 2025 |
| Christopher R. ClineCHIEF FINANCIAL OFFICER | Sale | 20,000 | $35.01 | $700.20K | 01 Dec 2025 | 03 Dec 2025 |
| Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sale | 67,115 | $36.00 | $2.42M | 04 Nov 2025 | 06 Nov 2025 |
| Sandra CalvinSVP, CHIEF ACCOUNTING OFFICER | Sale | 67,115 | $36.00 | $2.42M | 04 Nov 2025 | 06 Nov 2025 |
| Coughlin Timothy | Sale | 18,000 | $35.03 | $630.60K | 31 Oct 2025 | 04 Nov 2025 |
| Heerma PeterCHIEF COMMERCIAL OFFICER | Sale | 5,591 | $35.00 | $195.69K | 31 Oct 2025 | 04 Nov 2025 |
| Peter HeermaCHIEF COMMERCIAL OFFICER | Sale | 5,591 | $35.00 | $195.69K | 31 Oct 2025 | 04 Nov 2025 |
| Timothy CoughlinDirector | Sale | 18,000 | $35.03 | $630.60K | 31 Oct 2025 | 04 Nov 2025 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 27,128 | $30.12 | $817.07K | 29 Oct 2025 | 30 Oct 2025 |
| Eric M DubeCHIEF EXECUTIVE OFFICER | Sale | 27,128 | $30.12 | $817.07K | 29 Oct 2025 | 30 Oct 2025 |
| Dube Eric MCHIEF EXECUTIVE OFFICER | Sale | 92,872 | $30.38 | $2.82M | 28 Oct 2025 | 30 Oct 2025 |
| Heerma PeterCHIEF COMMERCIAL OFFICER | Sale | 2,662 | $30.00 | $79.86K | 28 Oct 2025 | 30 Oct 2025 |
| Peter HeermaCHIEF COMMERCIAL OFFICER | Sale | 2,662 | $30.00 | $79.86K | 28 Oct 2025 | 30 Oct 2025 |
| Eric M DubeCHIEF EXECUTIVE OFFICER | Sale | 92,872 | $30.38 | $2.82M | 28 Oct 2025 | 30 Oct 2025 |
Frequently Asked Questions
What is TVTX stock price today?
TRAVERE THERAPEUTICS INC (TVTX) is currently trading at $28.60. The stock has a 52-week range of $12.91 to $42.13 and a market capitalization of $2.64B.
Is TVTX a good stock to buy in 2026?
TRAVERE THERAPEUTICS INC has a P/E ratio of N/A (forward P/E: 6.7), a dividend yield of none, and 1-year performance of +61.2%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling TVTX stock?
There have been 65 insider transactions for TVTX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has TVTX stock performed over the past year?
TRAVERE THERAPEUTICS INC (TVTX) has returned +61.2% over the past 12 months. The stock traded between $12.91 and $42.13 during this period, and is currently at $28.60.
Which hedge funds own TVTX (TRAVERE THERAPEUTICS INC)?
0 tracked hedge funds currently hold TVTX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is TVTX's market cap and valuation?
TRAVERE THERAPEUTICS INC (TVTX) has a market capitalization of $2.64B. The trailing P/E ratio is N/A and forward P/E is 6.7. The stock is classified in the Healthcare sector.
What is TVTX's revenue and profitability?
TRAVERE THERAPEUTICS INC reported revenue of $490.73M with net income of N/A and a profit margin of N/A. The stock has a beta of 0.88.
What sector is TVTX in and who are its biggest institutional holders?
TRAVERE THERAPEUTICS INC (TVTX) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.